Suppression of HUVEC tissue factor synthesis by antisense oligodeoxynucleotide

Thrombosis Research

Volumn 122, Issue 1, 2008, Pages 99-107

  Stephens, Alick C ^a   Ranlall, Nancy F ^b   Rivers, Rodney P A ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

CD31; Endothelial cells; Oligodeoxynucleotide; Receptor mediated endocytosis; Tissue factor

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CD31 ANTIGEN; LIPOPOLYSACCHARIDE; PHOSPHOROTHIONATE; THROMBOPLASTIN;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; ENDOCYTOSIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN;

ANTIGENS, CD31; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; POLYLYSINE; THROMBOPLASTIN; UMBILICAL VEINS;

EID: 42649090819     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.08.021     Document Type: Article

References (51)

1. Camerer E., Kolsto A.-B., and Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 81 (1996) 1-41
2. Bach R. Initiation of coagulation by tissue factor. CRC Crit Rev Biochem 23 (1988) 339-368
3. Franco R.F., de Jonge E., Dekkers P.E., Timmerman J.J., Spek C.A., van Deventer S.J., et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood 96 2 (2000) 554-559
4. Konigsberg W., Kirchhofer D., Riederer M.A., and Nemerson Y. The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis. Thromb Haemost 86 3 (2001) 757-771
5. Heyderman R.S., Klein N.J., Daramola O.A., Hammerschmidt S., Frosch M., Robertson B.D., et al. Induction of human endothelial tissue factor expression by Neisseria meningitidis: the influence of bacterial killing and adherence to the endothelium. Microb Pathog 22 5 (1997) 265-274
6. Edgington T.S., Mackman N., Fan S.T., and Ruf W. Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouv Rev Fr Hematol 34 Suppl (1992) S15-S27
7. Mackman N. Gene targeting in hemostasis. Tissue factor. Front Biosci 6 (2001) D208-D215
8. Farsi A., Domeneghetti M.P., Brunelli T., Gori A.M., Fedi S., Gensini G.F., et al. Activation of the immune system and coronary artery disease: the role of anti-endothelial cell antibodies. Atherosclerosis 154 2 (2001) 429-436
9. Rivers R.P.A., Hathaway W.E., and Weston W.L. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol 30 (1975) 311-316
10. Hetland O., Brovald A.-B., Holme R., Gaudernack G., and Prydz H. Thromboplastin (tissue factor) in plasma membranes of human monocytes. Biochem J 228 (1985) 735-743
11. Lyberg T. Clinical significance of increased thromboplastin activity on monocyte surface- a brief review. Haemostasis 14 (1984) 430-439
12. Andoh K., Pettersen K.S., Filion-Myklebust C., and Prydz H. Observations on the cell biology of tissue factor in endothelial cells. Thromb Haemost 63 2 (1990) 298-302
13. Ryan J., Brett J., Tijburg P., Bach R.R., Kisiel W., and Stern D. Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood 80 4 (1992) 966-974
14. Kirchhofer D., Tschopp T.B., Hadvary P., and Baumgartner H.R. Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in homogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J Clin Invest 93 5 (1994) 2073-2083
15. Lentz B.R. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res 42 5 (2003) 423-438
16. Bevilacqua M.P., Pober J.S., Majeau G.R., Fiers W., Cotran R.S., and Gimbrone Jr. M.A. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 83 12 (1986) 4533-4537
17. Crossman D.C., Carr D.P., Tuddenham E.G., Pearson J.D., and McVey J.H. The regulation of tissue factor mRNA in human endothelial cells in response to endotoxin or phorbol ester. J Biol Chem 265 17 (1990) 9782-9787
18. Lipp P., Schwaller B., and Niggli E. Specific inhibition of Na-Ca exchange function by antisense oligodeoxynucleotides. FEBS Lett 364 (1995) 198-202
19. Zheng R.Q.H., and Kemeny D.M. Inhibition of gene expression by anti-sense oligodeoxynucleotides. Clin Exp Immunol 100 (1995) 380-382
20. Wang S., Lee R.J., Cauchon G., Gorenstein D.G., and Low P.S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci U S A 92 (1995) 3318-3322
21. Crooke S.T. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32 (1992) 329-376
22. Jansen B., Schlagbauer-Wadl H., Brown B.D., Bryan R.N., van Elsas A., Muller M., et al. BCL-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4 2 (1998) 232-234
23. Desjardins J.P., and Iversen P.L. Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo. J Pharmacol Exp Ther 275 3 (1995) 1608-1613
24. Webb A., Cunningham D., Cotter F., Clarke P.A., di Stefano F., Ross P., et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349 9059 (1997) 1137-1141
25. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 14 10 (1996) 376-387
26. Graham F.L., and Van de E.B.A. A new technique for the assay of infectivity of human adenovirus 1V DNA. Virology 52 (1973) 456-467
27. Carlos M.P., Lebkowski J.S., and Botchan M.R. High mutation frequency in DNA transfected into mammalian cells. Proc Natl Acad Sci U S A 80 (1983) 3015-3019
28. Keown W.A., Cambell C.R., and Kucherlapti R.S. Methods for introducing DNA into mammalian cells. In: Goeddel V.D. (Ed). Methods in enzymology (1990), Academic Press, New York 527-537
29. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., et al. Lipofectin: a highly efficient lipid-mediated DNA transfection procedure. Proc Natl Acad Sci U S A 84 (1987) 7413-7417
30. Pettenazzo A., Jobe A., Ikegami M., Abra R., Hogue E., and Mihalko P. Clearance of phosphatidylcholine and cholesterol from liposomes, liposome loaded with metaproterenol, and rabbit surfactant from adult rabbit lungs. Am Rev Respir Dis 139 (1989) 752-758
31. Meisner D., Pringle J., and Mezei M. Liposomal pulmonary drug delivery. J Microencapsul 6 (1989) 379-387
32. Stephens A.C., and Rivers R.P. Suppression of human monocyte tissue factor synthesis by antisense oligodeoxynucleotide. Thromb Res 85 5 (1997) 387-398
33. Ziegler-Heitbrock H.W.L., and Ulevitch R.J. CD14: cell surface receptor and differentiation marker. Immunol Today 14 (1993) 121-125
34. Sun J., Paddock C., Shubert J., Zhang H.B., Amin K., Newman P.J., et al. Contributions of the extracellular and cytoplasmic domains of platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31) in regulating cell-cell localization. J Cell Sci 113 (2000) 1459-1469
35. Newman P.J. The biology of PECAM-1. J Clin Invest 100 11 Suppl (1997) S25-S29
36. Jung G., Kohnlein G.W., and Luders G. Biological activity of the antitumor protein neocarzinostatin coupled to a monoclonal antibody by N-succinimidyl 3-(2-pyridyldithio) proprionate. Biochem Biophys Res Commun 101 (1981) 599-606
37. Scarpati E.M., Wen D., Broze Jr. G.J., Miletich J.P., Flandermeyer R.R., Siegel N.R., et al. Human tissue factor: cDNA sequence and chromosome localisation of the gene. Biochemistry 26 (1987) 5234-5238
38. Andrews B., Rehemtulla A., Fowler B., Edgington T., and Mackman N. Conservation of tissue factor primary sequence among three mammalian species. Gene 98 (1991) 265-269
39. Andrews B. Is the WKS motif the tissue-factor binding site for coagulation factor Vll. TIBS 16 (1991) 31-36
40. Jaffe E.A., Nachman R.L., Becker C.G., and Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52 (1973) 2745-2756
41. Muller A.M., Hermanns M.I., Skrzynski C., Nesslinger M., Muller K.M., and Kirkpatrick C.J. Expression of the endothelial markers PECAM-1, vWf, and CD34 in vivo and in vitro. Exp Mol Pathol 72 (2002) 221-229
42. van Oosten M., van de Bilt E., van Berkel T.J., and Kuiper J. New scavenger receptor-like receptors for the binding of lipopolysaccharide to liver endothelial and Kupffer cells. Infect Immun 66 11 (1998) 5107-5112
43. Pan L., Kreisle R.A., and Shi Y. Expression of endothelial cell IgG Fc receptors and markers on various cultures. Chin Med J (Engl) 112 2 (1999) 157-161
44. Shoji Y., Akhtar S., Periasamy A., Herman B., and Juliano R.L. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res 19 20 (1991) 5543-5550
45. Taylor Jr. F.B., Chang A., Ruf W., Morrissey J.H., Hinshaw L., Catlett R., et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33 (1991) 127-134
46. Erlich J., Fearns C., Mathison J., Ulevitch R.J., and Mackman N. Lipopolysaccharide induction of tissue factor expression in rabbits. Infect Immun 67 (1999) 2540-2546
47. Franco R.F., de Jonge E., Dekkers P.E., Timmerman J.J., Spek C.A., van Deventer S.J., et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood 96 2 (2000) 554-559
48. Biemond B.J., Levi M., ten Cate H., Soule H.R., Morris L.D., Foster D.L., et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal fab fragment against factor VII/VIIa. Thromb Haemost 73 (1995) 223-230
49. Kaikita K., Takeya M., Ogawa H., Suefuji H., Yasue H., and Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 188 (1999) 180-188
50. Carmeliet P., Moons L., Dewerchin M., Mackman N., Luther T., Breier G., et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N Y Acad Sci 811 (1997) 191-206
51. Matsuyama M., Yoshimura R., Akioka K., Okamoto M., Ushigome H., Kadotani Y., et al. Tissue factor antisense oligonucleotides prevent renal ischemia-reperfusion injury. Transplantation 76 5 (2003) 786-791